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ABSTRACT
Pharmacologic vitreolysis with ocriplasmin, a 27
kilodalton serine protease, is an effective
nonsurgical treatment option for vitreomacular
traction (VMT).Data fromphase III clinical studies,
including the Microplasmin for Intravitreal
Injection—Traction Release without Surgical
Treatment (MIVI-TRUST) and Ocriplasmin for
Treatment for Symptomatic Vitreomacular
Adhesion Including Macular Hole (OASIS)
studies, have demonstrated the treatment efficacy
of ocriplasmin for VMT and full-thickness macular
hole (FTMH). Subgroup analysis of these clinical
trials as well as post-marketing clinical series have
aided in patient selection by identifying features
associatedwithsuccessfulpharmacologic releaseof
VMT with ocriplasmin, including adhesion
diameter B1500 lm, absence of epiretinal
membrane, phakic status, and age younger than
65. As a first-in-class therapeutic, ocriplasmin and
its side effects have been carefully monitored by
the vitreoretinal community. The following
categories of related or possibly related adverse
events have been identified: acute reduction in
visual acuity, ERG changes, dyschromatopsia,
retinal tear or detachment, lens subluxation or
phacodonesis, abnormal pupillary reflex, retinal
vascular changes, and OCT ellipsoid zone
alterations. Adverse events have almost all been
transient with restoration of visual acuity;
however, in select patients, alterations may persist.
Keywords: Macular hole; Ocriplasmin;
Pharmacologic vitreolysis; Vitreomacular
adhesion; Vitreomacular traction; Vitreoretinal
interface
INTRODUCTION
Degeneration and liquefaction of the vitreous
gel with age ultimately leads to formation of a
posterior vitreous detachment (PVD),
characterized by the separation of the
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
F295F0601C8A111C.
M. A. Khan
Retina Division, Department of Ophthalmology,
Doheny Eye Center UCLA, Pasadena, CA, USA
M. A. Khan  J. A. Haller (&)
Retina Service, Wills Eye Hospital, Philadelphia,
PA, USA
e-mail: jhaller@willseye.org
Ophthalmol Ther (2016) 5:147–159
DOI 10.1007/s40123-016-0062-6
posterior cortical vitreous from the internal
limiting membrane [1]. While PVD represents
a normal process of the aging eye, incomplete
separation or focal adhesions of the vitreous gel
to the macula may result in abnormalities of the
vitreoretinal interface.
Advances in ophthalmic imaging have
focused our understanding of disorders
involving the vitreomacular interface. In 2013,
the International Vitreomacular Traction Study
(IVTS) Group introduced an optical coherence
tomography (OCT) based system for the
classification of vitreomacular interface disease
[2]. Specifically, the terms vitreomacular
adhesion (VMA), vitreomacular traction
(VMT), and full-thickness macular hole
(FTMH) were defined. FTMH was defined as a
foveal lesion involving all retinal layers. VMA
was defined as macular attachment of the
vitreous cortex within a 3-mm radius of the
fovea without change in retinal morphology.
VMT was differentiated from VMA by the
presence of retinal morphologic changes, but
without FTMH (Fig. 1). Both VMA and VMT
could be further classified by the size of
adhesion [focal (B1500 lm) or diffuse
([1500 lm)] as well as the presence or absence
of concurrent macular disease. FTMH was
classified as primary (due to VMT) or
secondary and further defined by size as small
(B250 lm), medium ([250 and B400 lm), or
large ([400 lm).
Resulting abnormalities in retinal
morphology from VMT commonly lead to
visual decline, including metamorphopsia,
visual field defect, and decreased visual acuity
[3]. Surgical management with pars plana
vitrectomy (PPV) has long been the mainstay
of VMT and FTMH treatment [4, 5]. However,
following the U.S. Food and Drug
Administration approval of intravitreal
ocriplasmin (Jetrea; ThromboGenics, Inc.,
Iselin, NJ, USA) for the treatment of VMT,
pharmacologic vitreolysis is now a viable
therapeutic option. Ocriplasmin, a 27
kilodalton serine protease, achieves its effect
via lysis of laminin and fibronectin at the
vitreoretinal interface and subsequent VMA
release [6].
As a first-in-class drug, clinical
understanding of ocriplasmin continues to
evolve over time. Experience from phase III
clinical trials and subsequent post-marketing
clinical series have provided added information
regarding the efficacy of ocriplasmin, expected
‘‘real-world’’ outcomes, patient selection, and
adverse event profiles. These topics are reviewed
below.
Fig. 1 Examples of vitreomacular traction (VMT) and full
thickness macular hole (FTMH). The International
Vitreomacular Traction Study (IVTS) Group deﬁned
abnormalities of the vitreoretinal interface. Vitreomacular
adhesion (VMA) was deﬁned as macular attachment of the
vitreous cortex within a 3-mm radius of the fovea without
change in retinal morphology. VMT was differentiated
from VMA by the presence of retinal morphologic changes
(a, b) but without full-thickness defect. FTMH was
deﬁned as a foveal lesion involving all retinal layers (c)
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Data from phase III clinical studies, including
the Microplasmin for Intravitreal
Injection-Traction Release without Surgical
Treatment (MIVI-TRUST) and Ocriplasmin for
Treatment for Symptomatic Vitreomacular
Adhesion Including Macular Hole (OASIS)
studies, have demonstrated the treatment
efficacy of ocriplasmin for VMT and FTMH
(Table 1).
The Microplasmin for Intravitreal
Injection-Traction Release Without
Surgical Treatment (MIVI-TRUST) Studies
Phase III data is available from two multicenter,
randomized, double-blind, placebo-controlled
clinical trials, referred to collectively as the
MIVI-TRUST studies, completed between 2008
and 2010 [6]. Outcomes revealed statistically
significant non-surgical achievement of primary
and secondary study endpoints as well as
improvement in visual acuity and visual
function compared to placebo. Based on these
results, the U.S. Food and Drug Administration
approved use of intravitreal ocriplasmin for the
treatment of VMT in 2012.
In the MIVI-TRUST studies, 464 of the 652
enrolled eyes received a single intravitreal
injection of 0.125 mg ocriplasmin with
follow-up to 6 months. At the day 28 post
injection time-point, eyes receiving
ocriplasmin exhibited greater release of VMA
(primary endpoint, 26.5% vs. 10.1%, p\0.001),
closure of macular hole (40.6% vs. 10.6%,
p\0.001), and presence of full posterior
vitreous detachment (13.4% vs. 3.7%,
p\0.001) compared to eyes receiving vehicle
injection [6].
Visual function, as measured by the National
Eye Institute Visual Function Questionnaire (NEI
VFQ-25), improved in eyes treated with
ocriplasmin in the MIVI-TRUST trials. Varma
Table 1 Data from phase III clinical trials: the Microplasmin for
Intravitreal Injection-Traction Release without Surgical Treatment
(MIVI-TRUST) and Ocriplasmin for Treatment for Symptomatic




































146 74 41.7 \0.001 30 0.163 24 Yes
VMT vitreomacular traction, FTMH full-thickness macular hole, RCT randomized controlled trial, ERG electroretinogram,
MIVI-TRUST Microplasmin for Intravitreal Injection-Traction Release without Surgical Treatment, OASIS Ocriplasmin
for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
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et al. revealed that eyes treated with ocriplasmin
had greater mean improvement in baseline NEI
VFQ-25 scores (mean change ?3.4 versus 0.7,
p = 0.005)andweremore likely tohavea[5-point
improvement in VFQ-25 scores (36.0% versus
27.2%, p = 0.03) compared to eyes treated with
vehicle injection [7]. In addition,eyes treatedwith
ocriplasmin had greater improvement in multiple
VFQ-25 sub-scale scores, including general vision
(p = 0.003), distance vision activities (p = 0.03),
and driving difficulty (p = 0.03), and were less
likely to have [5-point worsening of VFQ-25
composite scores (15.0% vs. 24.3%, p = 0.005)
compared to the placebo group [7].
Gandorfer et al. similarly analyzed visual
function in eyes enrolled in the MIVI-TRUST
trials, with added insight as to best-corrected
visual acuity (BCVA) [8]. The authors noted that
C2-line improvement in BCVA was more likely
in eyes treated with ocriplasmin at month 6
compared to vehicle injection (28.0% vs. 17.1%,
p = 0.003). Moreover, achievement of VMA
release or nonsurgical FTMH closure was
strongly associated with visual acuity gains.
Multivariate analysis revealed that in eyes with
VMT treated with ocriplasmin, resolution of
VMA at day 28 was associated with C2-line
improvement in BCVA [p = 0.006, odds ratio
(OR) 2.023]. This was also true in eyes with
FTMH, as nonsurgical hole closure at day 28 was
associated with C2-line improvement in BCVA
(p\0.001, OR 6.716).
Haller et al. performed post hoc subgroup
analysis of the MIVI-TRUST data to better identify
features associated with VMA release with
ocriplasmin treatment [9]. The authors reported
age younger than 65, VMA adhesion diameter
B1500 lm, phakic status, presence of FTMH, and
absence of ERM as factors associated with
nonsurgical resolution of VMA at day 28. In
regards to FTMH, non-surgical hole closure at
month 6 was correlated strongly with hole size, as
closure was achieved in 58.3% of holes B250 lm
(p\0.001 versus vehicle), 36.8% of holes[250 and
B400 lm (p= 0.009 versus vehicle), and in 0% of
holes[400 lm.
Ocriplasmin for Treatment
for Symptomatic Vitreomacular Adhesion
Including Macular Hole (OASIS)
Additional clinical trial data is available from the
OASIS study [10]. In this trial, 220 eyes were
randomized in a 2:1 fashion to either a single
injection of 0.125 mg ocriplasmin (146 eyes) or
vehicle injection (74 eyes). Follow-up in this study
was 24 months, considerably longer than that of
the MIVI-TRUST trials. In this study, statistically
significant nonsurgical release of VMT was
observed in eyes treated with ocriplasmin
compared to vehicle injection (41.7% versus
6.2%, p\0.01), similar to the findings of the
MIVI-TRUST trials. While FTMH closure occurred
at a higher rate in the ocriplasmin group, this did
not reach statistical significance (30% versus
15.4%, p= 0.163) [10].
OASIS data, with longer follow-up, also
revealed that the statistically significant
difference in VMT release rate with ocriplasmin
was maintained to 24 months post-treatment. In
addition, eyes initially treated with ocriplasmin
weremore likely toachieve aC2-linegain invisual
acuity at 2 years (50.5% versus 39.1%, p = 0.114),
regardless of initial VMT release and need for





Following commercial availability of
ocriplasmin, several clinical series have been
published which offer ‘‘real world’’ clinical
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outcomes with pharmacologic vitreolysis and
provide additional insights regarding patient
selection. Overall, factors associated with VMT
release from ‘‘real-world’’ clinical outcomes were
similar to those reported in post hoc analysis of
the MIVI-TRUST data (Table 2). Although
helpful in describing outcomes and offering
criteria to maximize VMT release rates, these
series are small, may include patients with
co-morbid macular diseases, and may reflect a
post hoc selection bias.
Outcomes and Factors Associated
with VMT Release
Singh et al. [11] and Kim et al. [12]
retrospectively reported outcomes in series of
17 and 19 eyes, respectively, treated with
intravitreal ocriplasmin. VMT release rates
were found to be 47.1% and 42.1%,
respectively, and FTMH closure rates of 80%
and 50%, respectively. Rates of release were
found commensurate or better than the
MIVI-TRUST data. Furthermore, Singh et al.
noted that VMT release rate improved if three of
the following four criteria were met: adhesion
diameter B1500 lm, absence of ERM, phakic
status, and age younger than 65. If all four
criteria were met, the release rate further
improved to 75% (3/4 eyes). Kim et al. also
reported that adhesion diameter B1500 lm,
absence of ERM, phakic status, and age
younger than 65 were associated with VMT
release in their study.
More recently, larger series were published
by Warrow et al. [13] and Sharma et al. [14].
Warrow et al. reported outcomes in 35 eyes and
reported a VMT release rate of 43% (15/35 eyes)
and FTMH closure rate of 17% (1/6 eyes). The
authors reported the following factors to be
associated with release of VMT: small adhesion
diameter (mean 346 versus 730 lm, p = 0.05),
transient outer layer abnormalities on OCT
(p = 0.008), younger age (p = 0.04), shorter
duration of VMT (mean 4.6 versus
10.4 months, p = 0.03), and absence of
concurrent retinal disease (p = 0.02). Sharma
et al. published outcomes of 58 eyes treated for
VMT and FTMH. At mean follow-up of
8.7 months, overall VMT release was observed
Table 2 Reported factors associated with successful pharmacologic vitreomacular traction (VMT) release with ocriplasmin
(0.125 mg)
Phakic status
Age younger than 65 years
Small adhesion diameter (B1500 lm)
Presence of full thickness macular hole
Absence of epiretinal membrane
Absence of concurrent retinal disease
Shorter duration of VMT
Transient outer retinal layer abnormalities on OCT
Macular hole size\250 lm
Macular hole ‘width factor’18 (basal diameter–minimum linear diameter)\60 lm
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in 29/58 eyes (50%) including in 4/15 eyes
(27%) with FTMH. While not achieving
statistical significance, the authors also noted
phakic status, age \65 years, absence of
epiretinal membrane to be associated with
VMT release, and greater FTMH closure in eyes
with hole sizes\400 lm.
Given that factors associated with VMT
release were reported by various authors,
Chatziralli et al. performed a meta-analysis to
determine pooled odds ratios and confidence
intervals (CI) for each factor reported to be
associated with VMT release in the literature
[15]. The following results were noted: age
\65 years (OR 2.69, 95% CI 1.79–4.03), female
gender (OR 2.37, 95% CI 1.23–4.57), adhesion
diameter \1500 lm (OR 7.85, 95% CI
3.80–16.24), phakic lens status (OR 3.02, 95%
CI 2.02–4.50), absence of ERM (OR 4.75, 95% CI
3.06–7.37), and FTMH size \250 lm (OR 2.25,
95% CI 1.12–4.53).
Macular Hole Closure
In the MIVI-TRUST trials, overall nonsurgical
macular hole closure rate was noted to be 40.6%
with ocriplasmin treatment, with success noted
for both small (58.3% versus 16.0%, p\0.001)
and medium (36.8% versus 5.3%, p = 0.009)
holes. However, ‘‘real world’’ outcomes of hole
closure have been lower than that found in the
MIVI-TRUST trials, including in series with
small and medium sized FTMH. For instance,
Miller et al. [16] and Sharma et al. [14] reported
a hole closure rates of 12.5% (1/8 eyes) and
28.6% (4/14 eyes), respectively, despite that
macular holes were sized\400 lm.
Further subgroup analysis of macular hole
cases has revealed additional insights. For
instance, Dugel et al. [17] noted that while
absence of epiretinal membrane was associated
with overall VMT release, rates of macular hole
closure were found to be similar in eyes with or
without concurrent epiretinal membrane
(38.9% versus 41.5%, respectively) in the
MIVI-TRUST trials. In addition, Dugel et al.
also noted that of eyes treated with ocriplasmin
who exhibited hole closure at 6 months (43
eyes), 55.8% exhibited VMA release at day 28
versus 44.2% who did not. Thus, a clear
association between presence or absence of
epiretinal membrane and VMA release with
hole closure was not present in the
MIVI-TRUST trial data.
To better identify OCT features that may
predict hole closure other than hole size, Steel
et al. prospectively evaluated outcomes in 31
eyes with idiopathic small or medium FTMH
treated with ocriplasmin [18]. Mean hole size
was 278 lm (range 80–395 lm). In addition to
hole size (defined by the minimal linear
diameter), the authors evaluated the
association between macular hole basal
diameter and a new index termed the ‘width
factor’ (defined as basal diameter minus the
minimal linear diameter). Overall, the authors
noted a VMA release rate of 61% (19/31 eyes)
and a hole closure rate of 35% (11/31 eyes). All
patients with hole closure exhibited VMA
release. On multivariate analysis, the authors
noted that ‘width factor’ was most strongly
predictive of hole closure (p\0.001), with a
‘width factor’ of \60 lm associated with hole
closure in 95% of cases. Notably, in these series
of small and medium FTMH, hole size alone was
not significantly predictive of VMA release or
hole closure.
Lastly, macular hole reopening has been
reported in the literature following prior hole
closure with ocriplasmin [19]. This was also
noted in the MIVI-TRUST trial, observed in 4/43
eyes (9.3%) treated with ocriplasmin at
6 months [6]. Prior authors have posited
tractional forces from epiretinal membrane
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formation as a possible etiology of hole
reopening post-ocriplasmin treatment [19].
Further data from prospective trials would be
helpful in clarifying factors associated with
macular hole closure, including the role of
VMA release and concurrent epiretinal
membrane, as a clear association between
these factors and macular hole closure is not
currently present. Such data may further help
refine ideal macular hole candidates, and may
explain why lower hole closure rates have been
reported in the literature compared to
MIVI-TRUST data.
OCULAR ADVERSE EVENTS
Ocular adverse events after use of this
first-in-class pharmacologic agent have
received special attention. In the phase III
MIVI-TRUST trials, patients receiving
ocriplasmin were more likely to experience
transient blurred vision (8.6% vs. 3.2%,
p = 0.01) and visual impairment (5.4% vs.
1.6%, p = 0.02) compared to vehicle injection
[6]. Following the commercial introduction of
ocriplasmin, several case reports describing
visual adverse events and abnormal OCT and/
or electroretinogram (ERG) findings were
reported [20–23]. Authors have suggested the
protease activity of ocriplasmin on laminin and
other proteins present in the intraretinal space,
and/or the physical effect of vitreous traction
release, as a possible etiologic factor [24];
however, a precise mechanism for these
adverse events and why such changes occur in
only selected patients is currently uncertain.
Categories of Adverse Events
The American Society of Retinal Specialists
(ASRS) Therapeutic Surveillance Committee
(TSC) evaluated both pre-marketing (clinical
trial data) and post-marketing adverse event
reports to better characterize ocular adverse
events presumed to be related to ocriplasmin
injection [25]. The following categories of
related adverse events were identified: acute
reduction in visual acuity, ERG changes,
dyschromatopsia, retinal tear or detachment,
lens subluxation or phacodonesis, abnormal
pupillary reflex, retinal vascular changes, and
OCT ellipsoid zone alterations. Shah et al., via
an online distributed survey to vitreoretinal
specialists, also sought to better characterize the
nature and rate of adverse events following
ocriplasmin injection, receiving a response rate
of 11% (270/2465 respondents) [26].
Considering data from the MIVI-TRUST trials
(Phase III data), the TSC analysis (voluntary
post-marketing event reports), and results from
the survey by Shah et al. (voluntary survey), the
following incidence of related or possibly related
adverse events in the literature include the
following: acute reduction in visual acuity
(1.3–16.95%); dyschromatopsia (0.5–9.09%);
retinal tear or detachment (0.4–2.65%); lens
subluxation or phacodonesis (0.02–0.38%);
abnormal pupillary reflex (0.3–1.8%); and
retinal vascular changes (0.05–0.28%) [6, 25, 26].
Data from the OASIS study did not reveal any
additional safety concerns or events with
follow-up to 24 months, and provided time to
resolution for many common visual complaints
post ocriplasmin injection. Notably, 27/146
patients (18.5%) in the ocriplasmin group
reported ‘visual impairment’ and an additional
13/146 patients (8.9%) reported ‘blurred vision’
in the OASIS trial [10]. Symptoms resolved in 39
of these 41 eyes (95%), with a median time to
resolution of 47 days in patients reporting
blurred vision and 16 days in those who
reported visual impairment.
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The TSC acknowledged that analysis of
post-marketing adverse events reports is
insufficient to determine a true incidence of
adverse events, as the voluntary and nonspecific
nature of the data gathered results in both
under-reporting and incomplete or
non-standardized follow-up reporting [25].
Caution should be applied to evaluation of
this information, as it may be subject to
over-interpretation, under-reporting, selection
bias, and recall bias.
Optical Coherence Tomography Changes
Post-Ocriplasmin Use
Several post-marketing reports have described
the nature of OCT changes following
ocriplasmin use, including ellipsoid layer
disruption and accumulation of subretinal
fluid (SRF, Fig. 2) [14, 27–30]. Notably,
ellipsoid zone alterations were not reported in
the MIVI-TRUST trial data, likely owing to the
use of time-domain OCT rather than
spectral-domain OCT (SD-OCT).
Larger case series have similarly observed
transient ellipsoid layer abnormalities on OCT
in 29–56% of treated patients [11, 13, 27, 28],
with OCT changes more common in patients
with VMT release [13, 28]. For instance,
Quezada-Ruiz et al. similarly reported
outcomes in 23 eyes receiving ocriplasmin for
VMT or FTMH and detailed the presence or
absence of ellipsoid layer changes [28]. Overall,
VMT release was noted in 11/23 eyes (47.8%)
and FTMH closure noted in 2/8 eyes (25%).
Overall, 10/23 eyes (43.47%) exhibited ellipsoid
layer alterations on OCT, of which seven eyes
(70%) exhibited VMT release and four eyes
(40%) exhibited acute visual acuity loss of two
lines or more. Ellipsoid layer alterations were
resolved in all eyes at one-month post injection.
Additional studies have sought to further
quantify and characterize ellipsoid changes as
well as presence of SRF. For instance, Itoh and
Ehlers quantitatively analyzed SD-OCT changes
in 19 eyes receiving ocriplasmin for VMT [30].
In this series, VMT release was noted in 9/19
eyes (47%). Overall, 10/19 eyes (53%) exhibited
transient ellipsoid layer disruption with mean
outer retinal thickness significantly reduced at
1 week post ocriplasmin injection (p\0.01)
with resolution at 1 month (p = 0.09) and
3 months (p = 0.91) versus baseline values. In
addition, the authors noted a correlation
between SRF accumulation and reduction in
Fig. 2 Optical coherence tomography alterations post
ocriplasmin use. A 62-year-old male with VMT of the
right eye (a). Following intravitreal injection of ocriplasmin,
VMT was released (b) at day 7. Ellipsoid layer attenuation
and accumulation of subretinal ﬂuid was present (arrows)
and vision decreased from 20/50 at baseline to 20/80.
Ellipsoid layer changes and subretinal ﬂuid progressively
resolved as shown at day 30 (c), day 60 (d), and day 90 (e).
Visual acuity was 20/25 on day 60 and was maintained
through the follow-up period thereafter
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ellipsoid zone-retinal pigment epithelium
(EZ-RPE) height (p = 0.00021, correlation
coefficient 0.88). Nudleman et al. similarly
evaluated ellipsoid layer alterations and SRF
accumulation in a series of 36 eyes with VMT
and/or small to medium sized FTMH [27]. VMT
release was noted in 15/36 eyes (42%), and
macular hole closure was observed in 7/9 eyes
(78%). Of the eyes with VMT release, 73% of
eyes (11/15 eyes) exhibited SRF accumulation
compared to 19% of eyes (4/21 eyes) without
VMT release. Overall, ellipsoid layer alterations
were noted in 56% of eyes (20/36 eyes), with
resolution in all cases at 1 year.
Electroretinogram Changes
Post-Ocriplasmin Use
A total of 18 reports of ERG changes were noted
in the MIVI-TRUST data, TSC analysis, and
survey of Shah et al. combined [6, 25, 26].
Two case reports with full-field ERG findings are
also available in the literature, one with and one
without FTMH. [21, 22] Findings were
notable for reduction in B wave amplitudes
during the scotopic ERG. Although A wave and
photopic abnormalities were also present, the
authors reported ERG findings were thought to
be most consistent with bipolar cell dysfunction
and reduced activity in primarily rod
photoreceptors.
The ERG sub-study of the OASIS trial was
completed to further clarify and describe ERG
changes over the 24-month follow-up period
[10]. Of the 220 patients enrolled in OASIS, 61
patients were ultimately analyzed in the ERG
sub-study. Of these 61 patients, 40 patients were
randomized to receive ocriplasmin and 21 to
receive sham injection. Patients underwent
full-field ERG following pupil dilation and
dark adaptation. A reportable ERG change was
defined in the sub-study as a[40% change from
baseline as read by a masked ERG expert at
central reading center [10].
In the sub-study, 16/40 eyes (40%) in the
ocriplasmin group had study-defined observable
ERG changes as compared to 1/21 eyes (4.8%) in
the sham group [10]. The data reported
indicated that ERG changes were more likely
to occur in eyes with VMT release and, over the
course of the study, eyes with ERG changes
maintained or gained visual acuity. Of the 16
eyes with ERG changes in the ocriplasmin
group, 13 eyes (81.3%) had resolution of ERG
changes by the conclusion of the study with a
median time to resolution of 6 months (range
21–449 days). Notably, a majority of eyes (10/16
eyes, 62.5%) with ERG changes in the
ocriplasmin group exhibited VMT release by
day 28, and a greater percentage (15/16 eyes,
94%) maintained or gained visual acuity at
study end. The ERG results, however, must be
interpreted in light of study limitations,
including that only 28% of patients in the
OASIS trial (61/220 patients) were analyzed in
the sub-study.
Long-term ramifications of OCT and ERG
abnormalities are not fully known and continue
to be investigated, but appear to be related to
pharmacologic VMT release with ocriplasmin.
The interesting lack of correlation with ultimate
visual acuity outcomes is also interesting and
worth noting. To date, all cases with reported
long-term outcomes have been transient with
restoration of visual acuity [10, 20, 22, 23, 27].
VITRECTOMY OUTCOMES
FOLLOWING OCRIPLASMIN USE
Vitrectomy has been shown to be an effective
treatment option for patients with VMT, with
well-characterized rare adverse events including
infection, hemorrhage, retinal detachment,
Ophthalmol Ther (2016) 5:147–159 155
macular hole, and loss of vision [4, 5]. In the
MIVI-TRUST trials, a total of 57/341
ocriplasmin-treated eyes (17.7%) and 46/169
placebo eyes (27.2%) that did not achieve
primary study endpoints by day 28 ultimately
underwent vitrectomy for VMT treatment by
month 6. In addition, of eyes that did meet
primary endpoints, 25/123 ocriplasmin treated
eyes (20.3%) and 4/19 placebo eyes (21.1%)
underwent vitrectomy by month 6 [6].
Surgical outcomes, intraoperative
complications, and postoperative
complications in patients undergoing
vitrectomy for VMT following use of
ocriplasmin have been favorable (Fig. 3). In a
multicenter, controlled interventional series,
Greven et al. retrospectively evaluated visual
acuity and surgical outcomes in 51 eyes of 51
patients undergoing vitrectomy for VMT or
FTMH who had already been treated with
ocriplasmin. Outcomes were compared to a
control group comprised of 22 eyes of 22
patients who had been offered ocriplasmin but
chose vitrectomy alone. Anatomic success
(release of VMT or closure of FTMH) was
achieved in 98% (50/51 eyes) of eyes in the
ocriplasmin treated group and 100% (22/22
eyes) in the control group. At 6 months, the
mean change in vision was similar between the
ocriplasmin and control groups (-0.17 versus
-0.23 LogMAR, p = 0.57).
Other authors have noted that OCT findings
commonly observed after ocriplasmin use,
including ellipsoid layer changes and SRF
accumulation, may continue to be observed
following subsequent vitrectomy. For instance,
Hager et al. reported a series of four eyes
undergoing vitrectomy for persistent VMT
after ocriplasmin. The authors noted the
presence of SRF in 3/4 eyes (75%), with SRF
resolution observed in all cases at 7 months
postoperatively.
CONCLUSION
Data from Phase III Clinical Trials and
post-marketing studies have expanded our
understanding of pharmacologic vitreolysis
with ocriplasmin. Ocriplasmin has been
demonstrated as an effective nonsurgical
therapy for VMT release and FTMH closure,
with patients on average experiencing
improvement in best-corrected visual acuity
and visual function. Importantly, careful
patient selection improves VMT release success
rates. Ocriplasmin has been carefully monitored
for adverse events, and these, particularly acute
but almost entirely self-limited visual
disturbances, are important for patient consent
and understanding. Structural changes on OCT
are common and often related to successful
VMT release, the etiology of which remains
Fig. 3 Surgical closure of macular hole after prior
treatment with ocriplasmin. A 6- year-old phakic male
with medium sized FTMH (a). Visual acuity was 20/100
at baseline. Following intravitreal injection of ocriplasmin,
the macular hole enlarged and VMT did not release (b).
Vision worsened to 20/400. Following vitrectomy surgery,
macular hole closure was achieved and vision improved to
20/80 (c) as shown on post-operative day 60
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incompletely understood. Overall, adverse
events have been largely transient, with
restoration of visual acuity; however, in select
patients, alterations may persist. Surgical
outcomes in eyes with a prior history of
ocriplasmin treatment have been favorable
and comparable to control eyes.
Future areas of interest include the efficacy of
ocriplasmin for VMT in patients with
concurrent macular disease and the role of
ocriplasmin for other vitreoretinal surgery
indications, including pediatric retinal
detachment and diabetic tractional
detachment. Additionally, trials directly
comparing outcomes with pneumatic
vitreolysis (intraocular perfluropropane gas or
sulfur hexafluoride gas) would be of special
interest in determining the relative efficacy of
ocriplasmin compared to treatment
alternatives. Prospective, phase IV studies in
addition to improved post-marketing reporting
of adverse events will be helpful in refining the
ongoing risk/benefit profile of ocriplasmin use.
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